Efficacy and safety of human recombinant endostatin plus pemetrexed and cisplatin in the treatment of advanced non-small cell lung cancer / 中华全科医师杂志

ABSTRACT

To explore the efficacy and safety of human recombinant endostatin (rh-endostatin) plus pemetrexed and cisplatin in the treatment of advanced non-small cell lung cancer (NSCLC).A total of 79 patients with advanced NSCLC were randomly divided into control group (n =39,pemetrexed plus cisplatin) and study group (n =40,rh-endostatin plus pemetrexed and cisplatin).The short-term relative risks of the test group (19/40,47.5％) was significantly higher than that in the control group (10/39,25.6％).And the clinical benefit rate the test group (33/40,82.5％) was higher than that of the control group (23/39,59.0％,P ＜ 0.05).The predominant adverse effects were bone marrow suppression and digestive reactions.And the incidence rate was not significantly different between two groups.